On March 28, a policy conference on the Hong Kong-Macao medical cooperation was held in Guangzhou.

As for now, there are 19 designated medical institutions regulated by the cooperation policy, and customs clearance between the mainland and Hong Kong and Macao has been fully resumed. Against this background,the Health Commission of Guangdong Province and the Food & Drug Administration of Guangdong Province are exploring ways to promote the high-quality development of the biomedical industry in Guangdong Province by leveraging the national policy.

Since the policy was put into practice in 2021, it has benefited over 2000 patients and is expected to help more people. "I hope that the designated medical institutions can strictly follow the Hong Kong-Macao medical cooperation policy in procedures such as application, procurement, transportation, storage, and use. In particular, they should monitor adverse reactions, and establish a prejudgment mechanism to effectively deal with such accidents," remarked Su Shengfeng, Inspector of the Food & Drug Administration of Guangdong Province.

Li Xuejun, an official of the Health Commission of Guangdong Province, believes that from the pilot period to the announcement of the newly designated medical institutions, the government has been steadily promoting the policy, so as to ensure its effective implementation and shape model executives. By continuously optimizing the approval process, the government has reduced the approval time to 1 working day.

In fact, the policy was stipulated to meet the medical demands of special groups. According to Li Xuejun, "since 2021, we have approved the application of 38 kinds of medical devices, with 86% of them been used in HKU-Shenzhen Hospital . Over 200 Hong Kong doctors have been employed by the hospital, with over 50 of them being practitioners. A designated medical institution with Hong Kong medical practitioners can better serve the residents of Hong Kong and Macao."

The price of imported medical devices is decided by four factors, namely, product prices, customs duties, VAT, and the cost of delivery. The sum of these four items is the price of imported medical devices in designated medical institutions, and hospitals can only offer them at this price. The market departments at all levels as well as health departments will monitor and inspect the execution annually.

In the future, more urgently-needed medicine will enter the mainland market through the medical cooperation mechanism.

“港澳药械通”政策如何落地公立医院？已获准药械审批时限为1个工作日

3月28日，由广东省药学会主办，广东省药学会药物警戒专业委员会和南方医科大学南方医院承办的“药械通·健康通—粤港澳大湾区‘港澳药械通’政策学术会议”在广州举办。

随着“港澳药械通”指定医疗机构增加至19家，内地和港澳恢复全面通关，三地间的交流更加密切，如何充分发挥国家政策优势，推进广东省生物医药产业高质量发展，聚焦提升大湾区居民幸福感、获得感、安全感？这也是当前广东省卫健委和省药监局十分关注的问题。

令人欣慰的是，在“港澳药械通”创新政策实施的两年时间里，受益患者超过两千人，且辐射范围不断扩大。广东省药品监督管理局一级巡视员苏盛锋指出：“希望指定医疗机构严格按照‘港澳药械通’政策，做好申请、采购、运输、储存、使用各方面工作，特别是对使用过程中不良反应的监测，建立预判，及时做好有效处置。”

广东省卫生健康委员会药政处处长李学钧认为，政策从试点到第二批指定医疗机构公布，稳中求进，确保政策有效推行，并且形成积极典型示范。政府部门已经不断优化审批流程，申报本机构已经获批准的药械，审批时限是1个工作日。

实际上，“港澳药械通”政策的目的就是解决特殊人群的治医疗服务问题。据李学钧介绍：“从药械用药的情况看，从2021年到现在，批准药械38种，港大深圳医院使用占比达到86%。我们知道港大深圳医院签约的香港医生有200多位，执业的有五六十位，所以如果进入药械通政策指定医疗机构有香港医生执业，可更加方便服务港澳居民。”

据了解，进口药械的价格主要包括4个部分，产品价格、关税、增值税以及配送公司的费用，这4项费用的总和就是指定医疗机构进口药械的价格，医院只能按照这个价格来执行，各级市场部门以及卫健部门将每年监督检查。

无疑，下一步将有更多内地急需的药械产品通过“港澳药械通”的方式引入。

文｜羊城晚报全媒体记者 张华
图｜受访者提供
翻译｜刘佳慧
校对 | 桂晴